ArticleMikrochimica acta2026
Self-enhanced electrochemiluminescence of gold nanoclusters via host-guest assembly for ultrasensitive protein biosensing.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Host-guest assembly-induced Au NCs (DMPDA@ ATT-Au NCs) with highly efficient self-enhanced electrochemiluminescence (ECL) were developed for sensitive detection of soluble urokinase-type plasminogen activator receptor (suPAR), a neotype biomarker in kidney diseases. Impressively, DMPDA@ ATT-Au NCs were assembled via host-guest recognition between the ligand 6-aza-2-thiothymine (ATT) protected Au NCs and the coreactant N, N-Dimethyl-1,3-propanediamine (DMPDA) through hydrogen-bond, which exhibited strong ECL signal due to the synergistic enhancement effect of the inhibition of non-radiative transitions by suppressing the rotation of the ligand ATT molecule and the reduction of energy loss by shortening the distance of electron transfer between the Au NCs and DMPDA. Furthermore, trace suPAR was transformed to enormous DNA network nanostructure with participation of high-efficiency dual-catalyst hairpin assembly (DCHA) system and DNA self-assembly, thereby significantly improving the detection sensitivity. Consequently, based on the DMPDA@ ATT-Au NCs as excellent ECL emitter and DCHA induced DNA network nanostructure as signal amplifier, the developed ECL biosensor realized the sensitive detection of suPAR with a detection limit (DL) of 1.48 fg/mL, which represents a sensitivity gain of about five orders of magnitude compared to a standard ELISA kit (DL: ng/mL). In three clinical samples, the biosensor showed excellent agreement with ELISA at high concentrations, and successfully quantified trace suPAR levels below the DL of ELISA kit. This strategy offers a novel ECL enhancement strategy of AuNCs to construct sensitive biosensing platform, which holds potential for extension to trace-level detection of other biomarkers toward clinical biomarker analysis, diagnostic evaluation, and treatment surveillance.
Indexed as
Identifiers
42171817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.